XynaRX

Vancouver, British Columbia–(Newsfile Corp. – March 14, 2019) – Vanity Capital Inc. (TSXV: VYC) (the “Company”) and XynaRx Pharmaceuticals Corp. (“XynaRx”) are pleased to announce the entering into of an arm’s length binding letter of intent (the “LOI”) accepted effective March 11, 2019, pursuant to which the Company will acquire all of the issued and outstanding shares in the capital of XynaRx.

March 14 news release:

https://stockhouse.com/news/press-releases/2019/03/14/vanity-capital-inc-enters-into-letter-of-intent-with-xynarx-pharmaceuticals

As described by XynaRx:

“XynaRx is a privately held British Columbia incorporated company focused on incorporating cannabidiol (“CBD”) in over-the-counter (“OTC”) healthcare products and generic medication. XynaRx intends to manufacture in-house and distribute its products in global markets. Management of XynaRx has developed a pipeline to introduce 15 OTC products and generic medications with CBD as an active ingredient (the “XynaRx Products”) over the next five years. Research and development will be conducted in-house for incorporating CBD in the 15 XynaRx Products and for conducting human trials.”

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Advertisements